These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38161697)

  • 21. Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer.
    Fu Q; Shen Q; Tong J; Huang L; Cheng Y; Zhong W
    Front Cell Dev Biol; 2021; 9():720472. PubMed ID: 34900985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.
    Guo Z; Cheng D; Xia Z; Luan M; Wu L; Wang G; Zhang S
    J Transl Med; 2013 Sep; 11():215. PubMed ID: 24044888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TNFR2: Role in Cancer Immunology and Immunotherapy.
    Yang Y; Islam MS; Hu Y; Chen X
    Immunotargets Ther; 2021; 10():103-122. PubMed ID: 33907692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
    Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
    J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
    Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
    Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.
    Li J; Wang S; Wang N; Zheng Y; Yang B; Wang X; Zhang J; Pan B; Wang Z
    Cell Commun Signal; 2021 Aug; 19(1):89. PubMed ID: 34461944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice.
    Zhang C; Lei L; Yang X; Ma K; Zheng H; Su Y; Jiao A; Wang X; Liu H; Zou Y; Shi L; Zhou X; Sun C; Hou Y; Xiao Z; Zhang L; Zhang B
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34642245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer.
    Aida K; Miyakawa R; Suzuki K; Narumi K; Udagawa T; Yamamoto Y; Chikaraishi T; Yoshida T; Aoki K
    Cancer Sci; 2014 Feb; 105(2):159-67. PubMed ID: 24289533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
    Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
    J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
    Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
    Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
    Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
    J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells.
    Guo Y; Xie F; Liu X; Ke S; Chen J; Zhao Y; Li N; Wang Z; Yi G; Shen Y; Li D; Zhu C; Zhang Z; Zhao G; Lu H; Li B; Zhao W
    J Mol Cell Biol; 2024 Nov; 16(6):. PubMed ID: 37935468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer.
    Zhu L; Zhang X; Chen X; Yang D; Nie Y; Pan R; Li L; Wang C; Gui H; Chen S; Jing Q; Wang M; Nie Y
    Biochem Biophys Res Commun; 2023 Apr; 653():106-114. PubMed ID: 36868074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
    D'Alise AM; Leoni G; De Lucia M; Langone F; Nocchi L; Tucci FG; Micarelli E; Cotugno G; Troise F; Garzia I; Vitale R; Bignone V; Di Matteo E; Bartolomeo R; Charych DH; Lahm A; Zalevsky J; Nicosia A; Scarselli E
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The TNF-α/TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response.
    Moatti A; Cohen JL
    Front Cell Dev Biol; 2021; 9():725473. PubMed ID: 34712661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
    Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
    Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
    Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.